2-(3-Bromo-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester | 330803-55-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(3-Bromo-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester
• CAS: 330803-55-9
• 化学式: C₁₇H₁₅BrN₂O₂
• 分子量: 359.222
• InChiKey: BTVJLCVJBOCPSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.27
• 重原子数：
  22.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  44.12
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2-(3-Bromo-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 在 三甲基铝 、 三氟乙酸 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 生成 2-(3-Bromo-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (2'-sulfamoyl-biphenyl-4-yl)-amide
  参考文献：
  名称：

  Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides

  摘要：

  Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00239-1
• 作为产物：
  描述：

  2-氨基-3-溴萘 在 盐酸 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 生成 2-(3-Bromo-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides

  摘要：

  Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00239-1